Royalty Pharma plc(RPRX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Royalty Pharma plc (RPRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RPRX at 71.8/100 on a 32-signal composite quality model, placing it at rank #171 of 2,962 stocks — the top 10% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Royalty Pharma plc reports quarterly revenue of $674.1M, net income of $17.9M. Top institutional holders of RPRX by reported 13-F value include MORGAN STANLEY, Capital International Investors, BlackRock, based on the most recent SEC filings. RPRX trades on the Nasdaq exchange and files with the SEC under CIK 1802768. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Royalty Pharma plc directly from SEC EDGAR.
AI Quality Score
71.8/100
AI Rank
#171
Revenue
$674.1M
Net Income
$17.9M
RPRX key financials by period
Royalty Pharma plc reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.4B
$770.9M
65.6%
FY 2024
10-K
$2.3B
$859.0M
57.1%
FY 2023
10-K
$2.4B
$1.1B
63.4%
FY 2022
10-K
$2.2B
$42.8M
13.7%
FY 2021
10-K
$2.3B
$619.7M
62.5%
FY 2020
10-K
$2.1B
$975.0M
75.2%
Institutions holding RPRX
Institutional investors reporting a position in Royalty Pharma plc on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
H1 2026 total revenue of $1.3B (+13.8% YoY) driven by $1.2B income from financial royalty assets (+13.1%), as cystic fibrosis franchise and Tremfya offset Evrysdi and Tysabri declines.
Biggest Revenue Drivers
Income from financial royalty assets$1,233.0M+13.1% YoY
Driven by Tremfya (+$38.4M), cystic fibrosis franchise (+$27.7M), Imdelltra acquisition (+$46.9M), and Voranigo (+$18.6M), partially offset by Evrysdi (-$89.1M allowance reversal) and Tysabri (-$154.5M allowance reversal).
Other royalty income and revenues$71.7M+25.8% YoY
Primarily driven by growth in Trodelvy sales and income from fully amortized assets.
Biggest Revenue Drivers
Total revenue: $1,304.7M+13.8% YoY
Income from financial royalty assets$1,233.0M+13.1% YoY
Driven by Tremfya (+$38.4M), cystic fibrosis franchise (+$27.7M), Imdelltra acquisition (+$46.9M), and Voranigo (+$18.6M), partially offset by Evrysdi (-$89.1M allowance reversal) and Tysabri (-$154.5M allowance reversal).
Other royalty income and revenues$71.7M+25.8% YoY
Primarily driven by growth in Trodelvy sales and income from fully amortized assets.
Largest Expense Items
Provision for changes in expected cash flows from financial royalty assets$70.7MExpense vs. $(331.1M) income YoY
Provision expense primarily related to Adstiladrin decline and cystic fibrosis franchise, offset by provision income on Tysabri and Evrysdi.
General and administrative expenses$321.4M+10.6% YoY
Higher share-based compensation ($229.6M) from Internalization, offset by elimination of $113.6M Management Fees post-Internalization.
Research and development funding expense$137.6M-60.8% YoY
Primarily related to JNJ-4804, litifilimab, and TEV-'408 funding, compared to $250M daraxonrasib upfront payment in prior year.
Interest expense$187.3M+39.9% YoY
Increase driven by $2.0B senior notes issued in September 2025 and $380M term loan from Internalization.
Margins: Operating income declined to $696.2M (-6.4% YoY) due to provision expense on financial royalty assets and higher interest costs, despite revenue growth. The company has higher fixed share-based compensation from the May 2025 Internalization, replacing prior external management fees.
Watch Items from the Filing
Vertex (cystic fibrosis franchise) accounted for 33% of revenue in H1 2026 (30% of current financial royalty assets). Dispute with Vertex since Q2 2025 regarding full royalty payments on Alyftrek's deuterated ivacaftor component remains unresolved.
Tazverik impairment charge of $69.4M in Q1 2026 after voluntary withdrawal announcement; total financial royalty assets include $1.6B unapproved assets at cost (frexalimab $522.6M, olpasiran, daraxonrasib, others).
Top five product franchises represent 59% of H1 2026 Royalty Receipts; significant portfolio concentration risk if any major product experiences market disruption or generic entry.
Internalization completed May 16, 2025 with $1.1B transaction value; 22.8M RP Holdings Class E Interests vest over 5-9 years with $570.9M unrecognized expense remaining; Employee EPAs fair value increased to $713.2M at June 30, 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
